See the DrugPatentWatch profile for Prolia
The price of Prolia (denosumab) without insurance can vary significantly based on factors such as location, pharmacy, and any available discounts or patient assistance programs. However, it is generally considered a high-cost medication.
How Much Does Prolia Cost Without Insurance?
Without insurance coverage, a single injection of Prolia can range from approximately $700 to over $1,000. This cost typically covers one 60 mg dose, which is administered every six months for conditions like osteoporosis.
What Factors Influence Prolia's Price?
Several elements contribute to the overall cost of Prolia. These include the manufacturing expenses, research and development investments, and the specialized delivery and storage requirements for biologic drugs. Additionally, market demand and competition from alternative treatments can influence pricing strategies. The list price set by the manufacturer is often higher than what insured patients pay due to negotiated discounts and rebates.
Are There Ways to Reduce the Cost of Prolia?
Patients without insurance may be eligible for patient assistance programs offered by the manufacturer, Amgen. These programs can provide Prolia at a reduced cost or for free to eligible individuals based on income and insurance status. Consulting with a healthcare provider or a hospital's financial assistance department can help identify these opportunities. Some pharmacies may also offer discount cards or programs that can lower out-of-pocket expenses.
When Does Prolia's Patent Expire?
Understanding patent expiry dates is crucial for anticipating potential cost reductions through generic or biosimilar alternatives. Information regarding Prolia's patent status and potential patent expiry dates is available on resources like DrugPatentWatch.com [1].
Who Makes Prolia?
Prolia is manufactured by Amgen, a global biotechnology company. Amgen is responsible for the development, production, and marketing of Prolia.
How Does Prolia Compare to Other Osteoporosis Treatments?
Prolia is a monoclonal antibody that works by inhibiting osteoclast activation and survival, thereby reducing bone resorption. It is prescribed for postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis at high risk for fracture, and individuals receiving certain cancer treatments. Alternative treatments for osteoporosis include bisphosphonates (e.g., alendronate, risedronate), hormone therapy, and anabolic agents. The choice of treatment depends on individual patient factors, risk assessment, and physician recommendation.
---
Sources
[1] DrugPatentWatch.com